- Home
- INSM vs UHAL Comparison
INSM vs UHAL Comparison
Compare INSM & UHAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- UHAL
- Stock Information
- Founded
- INSM 1988
- UHAL 1945
- Country
- INSM United States
- UHAL United States
- Employees
- INSM N/A
- UHAL 35100
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- UHAL Rental/Leasing Companies
- Sector
- INSM Health Care
- UHAL Consumer Discretionary
- Exchange
- INSM Nasdaq
- UHAL Nasdaq
- Market Cap
- INSM 12.5B
- UHAL 13.4B
- IPO Year
- INSM 2000
- UHAL N/A
- Fundamental
- Price
- INSM $73.15
- UHAL $70.63
- Analyst Decision
- INSM Strong Buy
- UHAL
- Analyst Count
- INSM 16
- UHAL 0
- Target Price
- INSM $84.29
- UHAL N/A
- AVG Volume (30 Days)
- INSM 1.7M
- UHAL 123.5K
- Earning Date
- INSM 10-31-2024
- UHAL 11-06-2024
- Dividend Yield
- INSM N/A
- UHAL N/A
- EPS Growth
- INSM N/A
- UHAL N/A
- EPS
- INSM N/A
- UHAL 2.45
- Revenue
- INSM $342,958,000.00
- UHAL $5,642,104,000.00
- Revenue This Year
- INSM $18.96
- UHAL $3.99
- Revenue Next Year
- INSM $41.96
- UHAL N/A
- P/E Ratio
- INSM N/A
- UHAL $28.93
- Revenue Growth
- INSM 22.13
- UHAL N/A
- 52 Week Low
- INSM $21.92
- UHAL $54.46
- 52 Week High
- INSM $80.53
- UHAL $79.04
- Technical
- Relative Strength Index (RSI)
- INSM 53.81
- UHAL 42.67
- Support Level
- INSM $70.94
- UHAL $67.28
- Resistance Level
- INSM $74.32
- UHAL $75.92
- Average True Range (ATR)
- INSM 3.01
- UHAL 1.69
- MACD
- INSM 0.45
- UHAL -0.41
- Stochastic Oscillator
- INSM 85.11
- UHAL 24.09
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
About UHAL U-Haul Holding Company
U-Haul Holding Co is an American moving truck, trailer, and self-storage rental company. The company also provides moving boxes, packing supplies, LPG (propane) refills, trailer hitch and wiring installation, storage container rentals, and other services. It has three reportable segments Moving and Storage, Property and Casualty Insurance, and Life Insurance. The majority of its revenue comes from the Moving and Storage segment.